The company made the first sale in the offering on April 20 and has now sold the total offering amount of $3,225,875. There is a sales commission worth $216,206 and a $40,000 reimbursement of the placement agent’s legal expenses, according to the filing.
In total, nine investors contributed to the financing. Viveve Medical did not specify an intended use of the proceeds in the filing.
Englewood, Colo.–based Viveve’s eponymous device uses cryogen-cooled monopolar radiofrequency tech designed to treat gynecological conditions.